Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs Roivant Sciences Ltd. Common Shares (ROIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Electric Vehicles and Future Mobility vs Roivant Sciences Ltd. Common Shares — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $27.56 (market cap $74.06M), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $25.09B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 338.8× KraneShares Electric Vehicles and Future Mobility's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Electric Vehicles and Future Mobility for 46 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| KARS | ROIV | |
|---|---|---|
Market Cap | $74.06M | $25.09B |
Volume | 2,546 | 5,738,571 |
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $41.81 |
52-Week Low | $27.25 | $16.04 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | — | $21.36B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →About Roivant Sciences Ltd. Common Shares
Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →
